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ABSTRACT
Despite their central importance in mammalian de-
velopment, the mechanisms that regulate the DNA
methylation machinery and thereby the generation
of genomic methylation patterns are still poorly un-
derstood. Here, we identify the 5mC-binding protein
MeCP2 as a direct and strong interactor of DNA
methyltransferase 3 (DNMT3) proteins. We mapped
the interaction interface to the transcriptional re-
pression domain of MeCP2 and the ADD domain of
DNMT3A and find that binding of MeCP2 strongly
inhibits the activity of DNMT3A in vitro. This effect
was reinforced by cellular studies where a global
reduction of DNA methylation levels was observed
after overexpression of MeCP2 in human cells. By
engineering conformationally locked DNMT3A vari-
ants as novel tools to study the allosteric regulation
of this enzyme, we show that MeCP2 stabilizes the
closed, autoinhibitory conformation of DNMT3A. In-
terestingly, the interaction with MeCP2 and its result-
ing inhibition were relieved by the binding of K4 un-
modified histone H3 N-terminal tail to the DNMT3A–
ADD domain. Taken together, our data indicate that
the localization and activity of DNMT3A are under the
combined control of MeCP2 and H3 tail modifications
where, depending on the modification status of the
H3 tail at the binding sites, MeCP2 can act as either
a repressor or activator of DNA methylation.
INTRODUCTION
The correct establishment andmaintenance ofDNAmethy-
lation patterns that are set during mammalian embryoge-
nesis by the de novo DNA methyltransferases, DNMT3A
and DNMT3B, depend on the accurate targeting and regu-
lation of DNA methyltransferases (DNMTs) (1–3). Mam-
malian DNMTs comprise two parts, a large multi-domain
N-terminal part and a C-terminal catalytic domain (CD)
(4,5). The N-terminal parts of DNMTs are important for
guiding the nuclear and sub-nuclear localization of the en-
zymes. They function as an interaction platform with other
proteins, DNA and chromatin, thereby regulating the cat-
alytic activity (1,6). Two defined sub-domains are present
in the N-terminal part of DNMT3A and DNMT3B (Fig-
ure 1A): a PWWP domain, which recognizes H3K36me3-
modified H3 tails (7–9), and an ADD domain, which binds
the N-terminus of histone H3 if K4 is unmodified (10–
12). Structural and biochemical work has shown that the
ADD domain of DNMT3A forms contacts with the CD
at two distinct interfaces (Supplementary Figure S1) (13),
an autoinhibitory site, where ADD binding hinders DNA-
binding and thereby inhibits the activity of the CD, and an
allosteric site, where binding does not lead to inhibition.
Different ADD residues are contacting the CD, depending
on the conformation adopted by the enzyme. For instance,
Y526 contacts the CD in the allosteric conformation, while
D531 contacts the CD in the autoinhibitory conformation.
The conversion ofDNMT3A from the autoinhibitory to the
open conformation was shown to be stimulated by bind-
ing of the unmodified H3 peptide to the ADD domain.
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Figure 1. Structures ofDNMT3proteins andMeCP2 and interaction ofMeCP2withDNMT3A. (A)Domain architecture ofmouseDNMT3A,DNMT3L
andMeCP2 annotated with the domain boundaries used in this work. (B)Western blot detection of His-DNMT3A after its pull-downwith theGST-tagged
N-terminal truncated MeCP2 (MeCP2N, residues 104–486). (C) Western blot detection of Myc-tagged DNMT3A after its pull-down by EYFP-tagged
MeCP2 following transient co-expression of both proteins in humanHEK293 cells. As a negative control, the pull-down was performed after co-expression
of DNMT3A with EYFP. See also Supplementary Figure S10. (D) Western blot detection of endogenous MeCP2 after its pull-down by DNMT3A using
mouse brain protein extracts. An immunoprecipitation using an IgG isotype control was included as negative control. NTD, N-terminal domain.
Through its binding, H3 induces a large movement of the
ADD domain, which leads to the activation of DNMT3A
(12–14). Several studies have recently shown that the activ-
ity of DNMT3 enzymes is regulated by the interaction with
the H3 tail not only in vitro, but also in cells (8,15–18).
The biological role of DNA methylation is mediated by
proteins, which specifically bind to DNA carrying methy-
lated cytosine (19). One important reader of DNA methy-
lation is the MeCP2 protein (Figure 1A) (20–23). It is
the founding member of a group of proteins containing
so called methyl-binding domains (MBDs), which bind to
DNA in a methylation specific manner (24). MeCP2 rec-
ognizes methylated DNA with a preference for CpG dense
islands (22,25), and its binding strength is strongly influ-
enced by the flanking sequence of the methylated CpGs
(26,27). Recently, binding of methylcytosine in non-CpG
contexts was also reported (28,29). In addition to the
MBD, MeCP2 contains a transcriptional repression do-
main (TRD), which serves as a protein recruitment platform
and shows a weak methylation-independent DNA binding
(23,30). MeCP2 is known to interact with various tran-
scriptional repressors and co-repressors, including Histone
Deacetylases, DNMT1, and the ATRX and Sin3A pro-
teins (31–34). Functionally,MeCP2 is involved in numerous
cellular processes, like methylation-induced gene repression
(in particular of long genes), control of repetitive elements,
chromatin compaction and looping and splice site regula-
tion (23,29,30,35–38). In addition to its role in gene silenc-
ing, gene expression studies performed in specific brain sub-
regions found altered expression levels of hundreds of genes
after loss of MeCP2, most of which were upregulated by
MeCP2 (39–41). These findings indicate that MeCP2 can
function as a gene activator or repressor depending on the
genomic context. Nevertheless, in spite of its high abun-
dance in adult neurons, important role in chromatin organi-
zation and strong clinical relevance, the mechanistic details
behind these opposing roles of MeCP2 are not fully under-
stood (42).
Both DNMT3A and MeCP2 are highly expressed in
neurons (35,43) (EBI expression atlas http://www.ebi.ac.
uk/gxa/) and they have important functions in the brain.
DNMT3A has been implicated in neuromuscular control,
synaptic plasticity, learning and memory (44–46). MeCP2
functions as a structural protein and forms a specific type
of chromatin, which is depleted of histone H1 (23). It plays
an essential role in brain plasticity (35) and inactivatingmu-
tations of the X-linked MECP2 gene were shown to cause
Rett syndrome, a severe neurodevelopmental disease asso-
ciated with developmental disorders and autism-like symp-
toms in females (30,34).
Since functional crosstalks between several readers and
writers of epigenetic modifications have been previously re-
ported (47) and DNMT3A and MeCP2 were both known
to be targeted to pericentromeric heterochromatin (48), we
investigated their potential interaction in this work. We ob-
served a strong binding of MeCP2 to DNMT3A in vitro,
in cells, and in the mouse brain and mapped the interac-
tion interface to the TRD domain of MeCP2 and the ADD
domain of DNMT3A. We found that binding of MeCP2
strongly inhibits the activity of DNMT3A by stabilizing its
autoinhibitory conformation. The inhibition of DNMT3A
was relieved by binding of an H3 tail peptide unmodified
at K4 to the ADD domain suggesting that MeCP2 controls
DNMT3A localization and activity depending on the local
chromatin context.
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MATERIALS AND METHODS
Generation of DNMT3A2 mutants andMeCP2 domain con-
structs
The murine DNMT3A and MeCP2 proteins and pro-
tein domains were prepared as indicated in Figure 1A.
The MeCP2 domains and mutant proteins were cloned in
pGEX-6P2 vector using BamHI and XhoI cloning sites. All
constructs were verified by DNA sequencing. Site-directed
mutagenesis were carried out by rolling circle polymerase
chain reaction (PCR) using a primer carrying point muta-
tion (49). The presence of the mutations was confirmed by
restriction marker analysis and by DNA sequencing.
Expression and purification of MeCP2 and DNMT3A pro-
teins
The MeCP2 domains and mutant proteins were expressed
in Escherichia coli BL-21 cells. Cells were cultivated in
Lysogeny broth (LB) medium at 37◦C while shaking un-
til an OD (600 nm) of 0.6–0.7 was reached. Then, protein
expression was induced by addition of 1 mM of isopropyl-
-D-thiogalactoside and the culture was incubated at 18◦C
shaking at 200 rpm overnight. The cells were harvested by
centrifugation (15 min at 4600 rpm) and the pellet resus-
pended in sonication buffer (20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (pH 7.5), 500 mM
KCl, 1mM ethylenediaminetetraacetic acid (EDTA), 1mM
dithiothreitol (DTT), 10% glycerol) including protease in-
hibitor (Sigma). The cells were lysed by sonication and cen-
trifuged at 18 000 rpm for 1 h to prepare a clear lysate, which
was applied on a GST-sepharose column (GE Healthcare).
After washing with sonication buffer, the protein was eluted
with sonication buffer containing 50 mM reduced glu-
tathione and dialyzed first against dialysis buffer I (20 mM
HEPES (pH 7.5), 200 mMKCl, 1 mM EDTA, 1 mMDTT,
10% glycerol) for 3 h, then against dialysis buffer II con-
taining 60% glycerol overnight. The purified proteins were
analyzed on 12% sodium dodecylsulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) gel stained with colloidal
Coomassie BB. The murine DNMT3A2 and DNMT3A–C
proteins were expressed and purified as described previously
(50–52). Since all DNMT3A structures were annotatedwith
numbers for the human proteins, we use human numbering
here. The residue numbers corresponding to human Q527,
D528 and D531 in murine DNMT3A are Q523, D524 and
D527, respectively. Examples of images of the purified pro-
teins used in this work are shown in Supplementary Figures
S2–S7.
GST pull-down experiments
For GST pull-down experiments, 20 l of Glutathione-
Sepharose 4B beads were washed with 200 l of interac-
tion buffer (25 mM Tris (pH 8.0), 100 mM KCl, 5 mM
MgCl2, 10% glycerol, 0.1% Nonident P-40 (NP-40), 200
M Phenylmethanesulfonyl fluoride (PMSF)). The beads
were incubated for 1 h at 4◦C with 10–15 g of the differ-
ent GST-tagged proteins, washed three times with interac-
tion buffer and incubated with His- or MBD-tagged pro-
teins (15 g) for 1 h at 4◦C with shaking. Then, the beads
were washed three times with wash buffer containing high
salt (25 mMTris (pH 8.0), 5 mMMgCl2, 300 mMKCl, 10%
glycerol, 0.1% NP40, 200 M PMSF). The interaction of
DNMT3A–ADD and MeCP2 TRDs was also investigated
using buffer containing up to 600 mM KCl. At last, the
beads were resuspended in sodium dodecyl sulphate (SDS)
gel loading buffer and incubated for 10 min at 95◦C. After
centrifugation of the beads at 14 000 rpm for 10 min, the
supernatant was loaded on a 12% SDS-PAGE gel. Proteins
were detected by western blotting or Coomassie BB stain-
ing as indicated. Some experiments were conducted in the
presence of recombinant histone H3.1 (Cat. No. M2503S,
New England Biolabs), as detailed in the ‘Results‘ section.
Co-immunoprecipitation assay
For co-immunoprecipitation of DNMT3A and MeCP2,
pcDNA-DNMT3A (expressing myc tagged DNMT3A)
and pEYFP-MeCP2 plasmids were co-transfected in
HEK293 cells. The pEYFPplasmidwas used as control. Af-
ter 48 h, the cells were collected and the cell pellets stored at
−80◦C. The cells were lysed as recommended by the GFP
trap protocol (ChromTek). Using GFP trap, YFP-tagged
MeCP2 was pulled-down and the complex washed with
buffer (10 mM Tris/Cl (pH 7.5), 0.5 mM EDTA, 0.5% NP-
40, 200 mM NaCl). The MeCP2 and DNMT3A proteins
were separated on a 12% SDS-PAGE and transferred to ni-
trocellulose membrane. To detect DNMT3A, the blot was
probed with anti-myc antibody (Santa Cruz, 1:1000 dilu-
tion) for 1 h at room temperature.
For immunoprecipitation of endogenous DNMT3A and
MeCP2, whole brains from 16-week-old C57Bl/N female
mice were used. Following mechanical disruption, the tis-
sue was lysed following a published protocol (53) with some
modifications. Three brains were homogenized in NP-40 ly-
sis buffer (10 mMHEPES (pH 7.9), 3 mMMgCl2, 10 mM
KCl, 10 mM NaF, 1 mM Na3VO4, 0.5 mM DTT, 0.5%
NP-40, 1× complete EDTA-free protease inhibitor cock-
tail (Roche)), by douncing 30× with a tight pestle, and pel-
leted at 1000 g. Lysates were next diluted 1:1 with Ben-
zonase buffer (10 mMHEPES (pH 7.9), 3 mMMgCl2, 280
mM NaCl, 0.2 mM EDTA, 10 mM NaF, 1 mM Na3VO4,
0.5 mM DTT, 0.5% NP-40) supplemented with 1× com-
plete EDTA-free protease inhibitor cocktail (Roche) and
sonicated with EpiShear (Active Motif) for 2 min 30 s (15
s ON, 30 s OFF cycles, 20% power, 3.2 mm microtip).
The homogenate was then digested with 500 units of Ben-
zonase (Novagen) for 2 h rotating at 4◦C. Chromatin pro-
teins were separated by centrifugation at 17 000 g for 20
min at 4◦C. For each pull-down, 2.5 mg lysate were pre-
cleared for 1 h at 4◦C with 20 mg Protein A Sepharose CL-
4B (GEHealthcare), followed by overnight incubation with
15 g anti-DNMT3A antibody (sc-2070, Santa Cruz). For
negative control, an equivalent amount of non-related rab-
bit IgG anti-myc (ab9106, Abcam) antibody was used. The
antibody-bound proteins were immobilized to 100 mg Pro-
tein A Sepharose CL-4B, blocked in 10% bovine serum al-
bumin (Roth) for 6 h rotating at 4◦C. After five washes with
immunoprecipitation buffer, the immune complexes were
eluted from the beads by boiling in 100 l Laemmli sam-
ple buffer. The samples were next analyzed by western blot
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as described above. For detection, anti-MeCP2monoclonal
primary antibody (#3456, Cell Signaling) was used, fol-
lowed by incubation with HRP-linked anti-rabbit IgG light
chain specific secondary antibody (211-032-171, Jackson
ImmunoResearch). Western lighting Ultra (Perkin Elmer)
was used as ECL HRP substrate.
Fluorescence microscopy
For sub-nuclear localization studies, NIH3T3 cells were
seeded on glass slides and transfected with plasmids ex-
pressing CFP- and YFP-tagged DNMT3L, DNMT3A–
ADD and MeCP2 using Fugene HD (Promega) accord-
ing to the manufacturer’s instructions. After 48 h, the cells
were fixed with 4% formaldehyde, mounted in Mowiol and
Z stacks images were collected using a Zeiss LSM 710 con-
focal microscope. Fluorescence signals were collected in
the YFP and CFP channels after confirming absence of
crosstalk (Supplementary Figure S8).
Substrates used for DNA methylation
The following oligonucleotide substrates were used for
DNA methylation assays: a biotinylated unmethylated 30
mer containing one CpG site (um30mer: TTG CAC TCT
CCT CCC GGA AGT CCC AGC TTC / Bt-GAA GCT
GGG ACT TCC GGG AGG AGA GTG CAA), the same
sequence hemimethylated at the CpG site with the methyla-
tion in the lower DNA strand (hm30mer: TTG CAC TCT
CCT CCC GGA AGT CCC AGC TTC / Bt-GAA GCT
GGG ACT TCmC GGG AGG AGA GTG CAA), a bi-
otinylated hemimethylated 30mer with optimized flanks for
methylation with DNMT3A (54) (hmF30mer: GAA GCT
GGA CAG TAC GTC AAG AGA GTG CAA / Bt-TTG
CAC TCT CTT GAmC GTA CTG TCC AGC TTC) and
a non-CpG substrate (nonCpG: GAA GCT GGT CCA
TTmC GAT GAT GGA GTG CAA / Bt-TTG CAC TCC
ATC ATmC GAA TGG ACC AGC TTC). The oligonu-
cleotides were annealed by heating to 86◦C for 5 min and
slowly cooling down to ambient temperature. In addition,
a biotinylated 585-mer DNA substrate obtained by PCR
was used that contains eight HpaII sites (CCGG) and 45
CpG sites (um585mer) (Supplementary Figure S9). The 585
mer was amplified from Lambda-phage DNA by PCR us-
ing the following primers: Bt-GAAGGA CAA CCT GAA
GTC CAG GTTG and GTG TAT GAC CAC CAG AGC
CTTTTGCand purified by PCRpurification kits (Qiagen).
To prepare partially methylated 585 mer (pm585mer), the
DNA was methylated with M.HpaII (NEB) following the
protocol of the provider and afterward purified by PCR pu-
rification kits. Successful pre-methylation atHpaII sites was
confirmed by HpaII (NEB) restriction digestion (Supple-
mentary Figure S9).
DNA methylation activity assay
The avidin–biotin microplate DNMT activity assay was
used to monitor the activity of different DNMT3A variants
in themethylation of biotinylatedDNAsubstrates, basically
as described (55,56). Each well of the microplate was coated
with 1g of avidin dissolved in 100l of 100 mMNaHCO3
(pH 9.6) and incubated overnight at 4◦C. Before starting the
assay, the wells were washed five times with 200 l of 1×
PBST (140 mMNaCl, 2.7 mMKCl, 4.3 mMNa2HPO4, 1.4
mMK2HPO4, 0.05% v/v Tween 50, pH 7.2) containing 0.5
M NaCl. The reaction mixtures were prepared containing
2.5MDNMT3A2 orDNMT3A–C and 3MMeCP2 (or
any of its domains) in methylation buffer (20 mM HEPES
(pH 7.2), 1 mM EDTA, 50 mM KCl, 1.25 mg/ml bovine
serum albumin). For the control reactions without MeCP2,
the same volume of dialysis buffer II was added instead of
the MeCP2. The reaction mixtures were incubated on ice
for 20 min and the wells of the plate were filled with 5 l of
0.5 M unlabeled AdoMet (Sigma) dispensed in 35 l 1×
PBST/0.5 M NaCl. Then, 1 M 30-mer oligonucleotide
DNA or 100 nM of 585-mer DNA and 0.76 M [methyl-
3H]-AdoMet (PerkinElmer Life Sciences) were added to the
reactionmixture and the samples were incubated at 37◦C. In
order to follow the time course of the reaction, aliquots of 2
l were removed from the reaction mixtures in duplicates at
time points between 2 and 30min and applied to one well of
the microplate where the incorporation of labeled AdoMet
was quenched by an excess of unlabeled AdoMet. This mix-
ture was incubated while slightly shaking for 30 min to 1 h.
The wells were washed five times with 200 l of 1× PBST
and 0.5 M NaCl. A buffer (100 l; 50 mM Tris–HCl (pH
8.0), 5 mM MgCl2) containing 0.7 g unspecific nuclease
from Serratia marcescens was added per well and the mix-
ture was incubated for 30–60 min with slight shaking. At
last, the released radioactivity was measured using liquid
scintillation counting and the average count per minute of
the duplicates was plotted against time. Linear regression
was used to obtain the slopes of the initial linear parts of
the time courses. The data are reported as averages and stan-
dard error of the mean (SEM) of at least two independent
experiments.
DNAmethylation analysis inHCT116DNMT1 hyphomorph
cells
To study the effect of MeCP2 on DNMT3A-mediated
methylation in cells, we used HCT116 DNMT1 hyphomor-
phic cells (HCT116D1hypo, kindly provided by Prof. Bert
Vogelstein, HHMI, USA), which have a reduced level of
global DNA methylation (57,58). HCT116D1hypo cells were
cultivated in McCoy’s 5A medium (Gibco catalog no.: 16
600) supplemented with 10% heat-inactivated calf serum,
2 mM L-glutamine (Sigma), 100 U/ml penicillin and 100
g/ml streptomycin at 37◦C in a saturated humidity at-
mosphere containing 5% CO2. HCT116D1hypo cells were
modified to express the ecotropic receptor and rtTA3 us-
ing retroviral transduction of pWPXLd-RIEP (pWPXLd-
rtTA3-IRES-EcoR-PGK-Puro) followed by drug selection
(0.8 ug/ml puromycin for 1week, respectively) similarly
as described (59). The resulting cell line was subsequently
transduced with ecotropically packaged retroviruses con-
taining the mecp2 gene fused to EYFP under control of
a TRE3G promoter. Retroviral gene transfer was per-
formed as previously described (60) using 10–20 g plas-
mid DNA and 5 g helper plasmid (pCMV-Gag-Pol, Cell
Biolabs) for each calcium phosphate transfection. Retrovi-
ral packaging was performed using PlatiniumE cells (Cell
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Biolabs). Transduction efficiencies of retroviral constructs
(TRE3G-MeCP2-EYFP-PGK-NEO and TRE3G-EYFP-
PGK-NEO) (61) were measured 48 h post induction with
1 g/ml doxycycline by flow cytometry (MACSQuant®
VYB, Miltenyi Biotec GmbH, Germany). Transduced cell
populations were selected 5 days post infection using 500
g/ml G418 (Gibco Life technologies). After 14 days of in-
duction,∼1 millionMeCP2 and the EYFP control express-
ing cells (as judged by being EYFP+) were sorted for each
replicate by flow cytometry (FACSAria III, BD, USA). Ge-
nomic DNAwas isolated using the DNAmini Kit (Qiagen)
and followed by LC-ESI-MS/MS analysis of DNA methy-
lation as described (62,63).
Quantitative RT-PCR
Quantitative RT-PCR assays were performed on a CFX96
Connect Real-Time detection system (Bio-Rad, Hercules,
CA, USA) using SsoFast EvaGreen supermix (Bio-Rad,
Hercules, CA, USA). For gene expression analysis, to-
tal RNA from 106 cells was isolated for each sample
using RNeasy Mini Kit (Qiagen, Limburg, The Nether-
lands). Complementary DNA (cDNA) was prepared using
MultiScribe™ Reverse Transcriptase (Applied Biosystems,
Thermo Fisher, USA) with oligo d(T)18 primers (NewEng-
land Biolabs, Ipswich, MA, USA) using 500 ng of RNA.
After this, quantitative PCR (qPCR) was carried out using
specific primers-sets for DNMT3A (CGA TTT CTC GAG
TCC AAC CCT G, ACC GGG AAG GTT ACC CCA),
DNMT3B (CAG TGA CAC GGG GCT TGA ATA TG,
CTT TGA GGA CTA GGT AGC CTG TCG CG) and
DNMT1 (GAG ACA CGA TGT CCG ACC TG, CCA
ATG CAC TCA TGT CCT TAC AG), normalized to the
housekeeping gene SDHA (TGG GAA CAA GAG GGC
ATC TG, CCA CCA CTG CAT CAAATT CAT). The rel-
ative DNMT expression was calculated using Ct (Expres-
sion = 2−Ct). Non-RT controls that did not undergo the
cDNA synthesis step were included in all experiments. Er-
ror analysis was based on independent cDNA preparations.
RESULTS
MeCP2 interacts with DNMT3A
To test whether DNMT3A and MeCP2 interact, we
first performed GST-pull-down assays using recombinant
murine full-length (FL) proteins.MeCP2 could be obtained
with good purity after generating a version lacking the N-
terminal unstructured domain (MeCP2N) (Supplemen-
tary Figure S2). As shown in Figure 1B, a robust pull-down
of DNMT3A by GST-MeCP2N could be detected. En-
couraged by the strong and direct interaction detected in
the in vitro assay, we next tested whether DNMT3A and
MeCP2 can also interact in cells. For this, HEK293 cells
were transiently co-transfectedwithMyc-taggedDNMT3A
and EYFP-tagged MeCP2 (Supplementary Figure S10).
To isolate immunocomplexes, the EYFP-tagged MeCP2
was immunoprecipitated and the pull-down material was
tested for the presence of Myc-DNMT3A. As shown in
Figure 1C, co-purified Myc-DNMT3A was detected after
co-expression with EYFP-MeCP2, but not with the EYFP
control. To exclude potential artifacts related to protein
overexpression, we finally performed immunoprecipitation
of endogenous DNMT3A frommouse brain, a tissue where
both MeCP2 and DNMT3A are abundantly expressed. As
shown in Figure 1D, MeCP2 could be specifically detected
in the pulled-downmaterial, but not in the IgG control. To-
gether, these results demonstrate that in addition to their
direct in vitro interaction DNMT3A and MeCP2 also as-
sociate after transient co-expression in mammalian cells as
well as at endogenous levels in brain extracts.
MeCP2 interacts with the ADD of DNMT3 proteins
Having established that the interaction between DNMT3A
and MeCP2 is not an artifact of the in vitro pull-down as-
say, but is also detected in biological relevant context, we
were next interested to pinpoint the interaction interfaces
between these two proteins. For this, we have undertaken
a systematic domain mapping approach by performing in
vitro pull-down experiments with serially truncated recom-
binant DNMT3A and MeCP2.
To define the interaction interface on DNMT3A, we first
performed GST pull-downs using MeCP2N-GST and
DNMT3A2, a naturally occurring isoform of DNMT3A,
which lacks 219 N-terminal amino acids reported to be
involved in DNA binding (Figure 1A) (64,65). As docu-
mented in Figure 2A, a robust pull-down was detected with
DNMT3A2 indicating that residues 1–219 of DNMT3A
are not required for the interaction withMeCP2. To further
define the interacting area, we next resorted to DNMT3L,
an important regulatory member of the DNMT3 fam-
ily, which shares the ADD domain with DNMT3A and
DNMT3B, while containing a crippled CD and lacking
the N-terminal part and the PWWP domains (Figure 1A).
The direct interaction detected between DNMT3L and
MeCP2N (Figure 2B) suggested that the association with
MeCP2 occurs through an interface that is shared between
DNMT3L and DNMT3A. To test this hypothesis, we next
performed pull-downs with the CDs of DNMT3A (Fig-
ure 2C) and DNMT3L (Figure 2D), respectively. Both of
these did not show an interaction with MeCP2N. By
contrast, a robust interaction could be detected between
the GST-tagged ADD domain of DNMT3A as bait and
a GST-cleaved MeCP2N as prey (Figure 2E). No signal
was detectable for the NTD and the PWWP domains of
DNMT3A in line with the results obtained for DNMT3L
and DNMT3A2. Taken together, these results show that
MeCP2 interacts with DNMT3 proteins via their ADD, a
domain that has been already reported to serve as a protein–
protein interaction platform and be essential for the regula-
tion of DNMT3 proteins.
DNMT3A interacts with the TRD of MeCP2
Having successfully mapped the interaction interface on the
DNMT3A side, we were next interested to dissect which
part of MeCP2 is responsible for the binding to DNMT3A.
To this end, we performed pull-downs with GST-tagged
MeCP2 domains. As shown in Figure 2F, out of the five
tested domains an interaction was detectable only for the
TRD. Pull-downs using the isolated MeCP2–TRD and
DNMT3A–ADD (Figure 2G) confirmed the direct and
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Figure 2. The ADD domain of DNMT3 proteins interacts with the TRD of MeCP2. (A) Coomassie staining of the pull-down of His-DNMT3A2 by
GST-MeCP2N. (B) Coomassie staining of the pull-down of His-DNMT3L by GST-MeCP2N. (C) Coomassie staining of the pull-down of MBP-
DNMT3A–C by GST-MeCP2N. A signal can be only detected in the input lane. See also Supplementary Figure S15. (D) Western blot detection of the
pull-down of His-DNMT3L-C by GST-MeCP2N. A signal is visible only in the input lane. (E) Western blot detection of the pull-down of MeCP2N
with different GST-tagged DNMT3A domains. For this experiment, GST-cleaved MeCP2N was used. The endogenous His-tag in MeCP2-CTDb was
used for detection. Out of the three tested DNMT3A domains, only the ADD domain displayed an interaction with MeCP2. (F) Western blot detection of
the pull-down of DNMT3A by different GST-tagged MeCP2 domains documenting an interaction with the MeCP2 FL, MeCP2N and MeCP2–TRD
domain. (G) Coomassie detection of the pull-down of MBP–DNMT3A–ADD by wild-type GST-TRD domain (wt) or TRD containing the R306C Rett
mutation (RC), under two different salt concentrations. See also Supplementary Figures S11–S14.
self-sufficient interaction between these domains. The in-
teraction of MeCP2–TRD and DNMT3A–ADD was fur-
ther confirmed byAlpha-assay (Supplementary Figure S11)
and gel filtration (Supplementary Figure S12). Having iden-
tified the domains responsible for mediating the interac-
tion between these two proteins, we next tested the stabil-
ity and strength of the association between MeCP2–TRD
and DNMT3A–ADD by performing pull-downs under in-
creasingly high salt concentrations. Strikingly, we could re-
trieve comparable amounts of DNMT3A–ADD at both
300 and 600 mM KCl, indicating that its interaction with
MeCP2 TRD is strong and not driven by electrostatic in-
teractions (Figure 2G). A salt resistant and strong interac-
tion of MeCP2–TRD was also observed with DNMT3A2
(Supplementary Figure S13). Pull-down experiments in the
presence of the non-specific and highly active nuclease from
S. marcescens demonstrated that the interaction of both
proteins was not mediated by nucleic acids (Supplementary
Figure S14). SinceMeCP2 is mutated in the Rett syndrome,
we also tested the effect of the R306C Rett mutation in the
TRDdomain ofMeCP2 on the interactionwithDNMT3A,
but did not observe any change when compared with wild-
type TRD (Figure 2G).
MeCP2 influences the sub-nuclear localization of DNMT3L
and the DNMT3A–ADD domain
Having shown the direct interaction of MeCP2 with
DNMT3 proteins, we next aimed to study the influ-
ence of this interaction on the cellular localization of
these factors. MeCP2 is known to accumulate at peri-
centromeric heterochromatin (22,48,53), which clusters in
characteristic DAPI-dense foci in mouse fibroblasts. Un-
like MeCP2, the regulatory factor DNMT3L was shown
to have an almost homogenous nuclear distribution (66).
Expressing the fluorophore-tagged DNMT3L and MeCP2
in mouse fibroblasts confirmed the published localization
patterns of both proteins (Figure 3A and C). Notably,
co-expressing DNMT3L with MeCP2 led to a clear re-
targeting of DNMT3L toward chromocenters (Figure 3D
and F). This finding confirms the intracellular interaction
of DNMT3L andMeCP2 and indicates that the expression
of MeCP2 causes a re-distribution of the regulatory fac-
tor DNMT3L toward heterochromatin. Moreover, it shows
that the MeCP2 interaction influences chromatin target-
ing of DNMT3L. However, the physiological role of the
interaction of DNMT3L and MeCP2 is unclear, because
DNMT3L does not appear to play amajor role in the brain.
Unlike DNMT3L, DNMT3A is strongly enriched at
pericentromeric heterochromatin (52,66) (and references
therein), where it co-localizes with MeCP2 (48). This natu-
ral co-localization precluded direct studies of the effect of
MeCP2 on the localization of DNMT3A. To circumvent
this caveat, we performed localization studies with the flu-
orescently tagged DNMT3A–ADD domain. This showed
a diffuse nuclear localization when transfected alone in
mouse fibroblasts (Figure 3B). Similar to DNMT3L, after
its co-expression with CFP-tagged MeCP2, the ADD do-
main showed a preferential enrichment at heterochromatic
foci, indicating aMeCP2-mediated targeting to heterochro-
matin (Figure 3E and F). These results confirm that the
ADD domain interacts with MeCP2 in cells and demon-
strate that through its binding MeCP2 recruits DNMT3L
and DNMT3A–ADD to pericentromeric heterochromatin.
The interaction with MeCP2 inhibits the catalytic activity of
DNMT3A
To elucidate the function of the interaction betweenMeCP2
and DNMT3A, we next measured the in vitro rates of
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Figure 3. Transient expression of MeCP2 alters the cellular localization of DNMT3L and DNMT3A–ADD in NIH3T3 cells. (A) Representative fluo-
rescence microscopy images documenting the localization of CFP-DNMT3L upon its overexpression in mammalian cells. A predominantly homogenous
nuclear distribution is observed. (B) Representative fluorescence microscopy images documenting the localization of YPF-ADD upon its overexpression
in mammalian cells. A predominantly homogenous nuclear distribution is observed. (C) Representative fluorescence microscopy images documenting the
chromocenter-enriched localization of YFP-MeCP2 (left) and CFP-MeCP2 (right) upon their overexpression in mammalian cells. (D) Representative fluo-
rescence microscopy images showing that upon their co-expression DNMT3L is recruited to MeCP2 clusters. (E) Representative fluorescence microscopy
images showing that upon their co-expression DNMT3A–ADD is recruited to MeCP2 clusters. The scale bars correspond to 10 m. (F) Quantification of
the fraction of cells showing spotty and diffuse localization patterns in the experiments shown in panels (A–E) (based on analysis of >20 individual cells
in each case). See also Supplementary Figure S8.
DNAmethylation byDNMT3A2 in the presence ofMeCP2
or its TRD domain. The activity of DNMT3A has been
shown to be modulated by the target site, where CpG
is preferred over CpA (67–69), the flanking sequence of
CpG sites (70,71) and the length of the DNA substrates
(72). To study all these different properties, six different
DNA substrates were used for our DNA methylation ex-
periments (Figure 4): (i) an unmethylated 30-mer oligonu-
cleotide (um30mer), (ii) the same substrate in hemimethy-
lated form (hm30mer), (iii) a hemimethylated 30 mer with
an optimized flank for DNMT3A (hmF30mer) (54), (iv) a
585-mer PCR fragment (um585mer), (v) the 585-mer PCR
fragment pre-methylated at HpaII sites (pm585mer) and
(vi) a 30-mer oligonucleotide non-CpG substrate (non-CpG
30 mer).
Using 2.5 M DNMT3A2 and 3 M MeCP2, we con-
sistently observed that the interaction of MeCP2 with
DNMT3A2 resulted in ∼40–60% reduction in DNMT3A2
activity with the unmethylated substrates (Figure 4A and
B). Similar results were obtained with a truncated form
of DNMT3B corresponding to DNMT3A2 (Supplemen-
tary Figure S6). The activity of DNMT3A2 was further
reduced by ∼80% with methylated substrates, which can
be attributed to the better binding of MeCP2 to methy-
lated DNA via its MBD. We speculated that binding of
MeCP2 to pre-methylated DNA might target DNMT3A2.
To test this hypothesis, a partiallymethylated 585-merDNA
substrate was prepared by methylation with HpaII, an en-
zyme that exclusively methylates CG sites found within
CCGG motifs (Supplementary Figure S9). However, even
on this substrate, we observed inhibition of the activity of
DNMT3A2 by MeCP2 (Figure 4B, pm585mer). As a con-
trol, we used DNMT3A–C, which lacks the ADD domain
and does not interact with the MeCP2–TRD (Supplemen-
tary Figure S15), and observed that MeCP2 did not inhibit
its activity (Figure 4C).
Having mapped the interaction interface to the TRD of
MeCP2, we next tested whether this isolated domain can
also inhibit the activity of DNMT3A2 and observed 40–
70% inhibition with the different substrates (Figure 4D).
Non-CpGmethylation has recently been detected in consid-
erable amounts in human ES cells and neurons, and it was
connected to DNMT3A activity (28,73–75). We, therefore,
also investigated the influence ofMeCP2–TRD on the non-
CpG methylation activity of DNMT3A2 using a 30-mer
oligonucleotide substrate that contains one already methy-
lated CpG site, such that additional methylation could only
occur at non-CpG sites. As with the other DNA substrates,
we observed a similar inhibition of DNMT3A2 activity
by TRD (Figure 4D, non-CpG 30 mer), indicating that
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Figure 4. MeCP2 (A–C) andMeCP2–TRD (D and E) inhibit the activity of DNMT3A2 on a broad range of substrates. In vitroDNAmethylation kinetics
was conducted with 2.5 M DNMT3A2 (A and B) or DNMT3A–C (C) in the presence of 3 M MeCP2 (A–C) or MeCP2–TRD (D). In each panel,
identical control reactions without addition of MeCP2 or MeCP2–TRD were used to calculate relative activities. Different DNA substrates were used as
indicated. (E) Inhibition of DNMT3A2 at increasing concentrations of MeCP2–TRD in kinetics using um30mer as substrate. Reactions with DNMT3A–
C were performed in parallel since this domain does not interact with MeCP2–TRD. Control refers to reactions without added TRD. Panel (A) shows
methylation kinetics of hmF30mer as an exemplary primary data set. Bars show averages and SEM based on 2–3 independent experiments. See also
Supplementary Figures S6, S13 and S14.
CpG and non-CpGmethylation are equally inhibited by the
TRD interaction.
At last, we tested the activity of DNMT3A2 in the
presence of increasing amounts of TRD and observed
that the methyltransferase activity was strongly inhibited
(>95%) using a 2.4-fold excess of TRD (6 M with 2.5
M DNMT3A2) (Figure 4E). These results were fitted by
a binding constant (KD) of TRD to DNMT3A2 of 2.8 M
under catalytic conditions. As a control, the same experi-
ments were conducted with DNMT3A–C, but only a very
weak reduction of activity was observed (Figure 4E) indi-
cating that the inhibition of DNMT3A2 by TRD is not
caused by competition for the DNA substrate. This is an
important control, since TRD was reported to weakly bind
DNA (76,77). In summary, our results indicate that the
interaction between the TRD domain of MeCP2 and the
ADD domains of DNMT3A and DNMT3B results in a
direct and very strong inhibition of the DNMT activity at
both CpG and non-CpG sites.
MeCP2 overexpression reduces DNA methylation in
HCT116 cells
Based on the strong influence of MeCP2 on the activ-
ity of DNMT3 proteins, we were next interested to see if
the inhibitory effects on DNMT3A activity observed in
in vitro assays are also re-capitulated in a cellular context.
For this we resorted to the HCT116 DNMT1 hypomorphic
colon cancer cell line, which contains a truncated DNMT1
with reduced activity, but active copies of DNMT3A and
DNMT3B (57,58). Because of the impaired maintenance
DNA methylation activity, these cells have an ∼20% re-
duced amount of DNA methylation, which is more de-
pendent on the activity of DNMT3A and DNMT3B. This
makes theHCT116D1hypo cell line a suitablemodel system to
study the effect of the inhibition of DNMT3A by MeCP2.
We genomically integrated EYFP-fusedMeCP2 or only the
fluorophore as control by viral transduction and selected
for stably expressing clones. Expression of MeCP2 or fluo-
rophore control was induced for 14 days. Afterward, EYFP-
MeCP2 or fluorophore expressing clones were enriched by
fluorescence-activated cell sorting (Figure 5A). Genomic
DNAwas isolated and the global levels of 5-methylcytosine
were quantified by liquid chromatography-mass spectrom-
etry (LC-MS/MS). As shown in Figure 5B, we observed a
15% decrease in global DNA methylation. Expression lev-
els of all DNMTs were determined by qPCR indicating a
slight increase in DNMT3A expression, and no changes in
DNMT1 and DNMT3B (Figure 5C), showing that the re-
duction in DNAmethylation was not caused by reduced ex-
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Figure 5. MeCP2 reduces global DNA methylation in HCT116 cells containing a DNMT1 hypomorphic allele. (A) Flow cytometry analysis of EYFP-
MeCP2 andEYFP expression inHCT116D1hypo cells. The signal range used for sorting is indicated. (B)GlobalDNAmethylation levels after overexpression
of EYFP-MeCP2 in human HCT116D1hypo cells. EYFP-transfected cells were used as control. (C) Expression levels of all DNMTs in the HCT116D1hypo
cells expressing EYFP-MeCP2 or EYFP control. SDHA was used as reference gene. The error bars represent the SD based on two repeats.
pression of any of the DNMTs. Since DNMT1 interaction
with MeCP2 was reported not to cause a reduction in cat-
alytic activity (32), this result indicates that overexpression
of MeCP2 reduces the activity of DNMT3 enzymes in cells.
The TRD domain inhibits DNMT3A2 activity by an al-
losteric mechanism
We next aimed to mechanistically analyze the striking in-
hibitory effect of MeCP2 on DNMT3A. As described
above, structural studies showed that the ADD domain of
DNMT3A can dock on the CD at two alternative sites: an
allosteric and an autoinhibitory one (13). Binding of the
H3 tail peptide to the ADD domain was shown to stabilize
the allosteric conformation and thereby activate DNMT3A
(13,14). To investigate the mechanism of the repression of
DNMT3A by the TRDdomain, we engineeredDNMT3A2
variants containingmutations at Y526 orD531 in the ADD
domain, two critical residues involved in the two binding
sites at the CD (Supplementary Figure S1) in order to
selectively disrupt or strongly destabilize one of the two
DNMT3A conformations. Y526E was introduced to dis-
rupt the allosteric and D531R to disrupt the autoinhibitory
conformation. After confirming that both mutants still in-
teract with MeCP2–TRD (Supplementary Figure S16), we
investigated if these conformationally locked DNMT3A
variants still respond to the presence of the TRD. As shown
in Figure 6A, the inhibitory effect of MeCP2 was specifi-
cally lost in the D531R variant that can no longer adopt
the autoinhibitory conformation. This finding suggests that
MeCP2 reduces the activity of DNMT3A by an allosteric
mechanism, in which TRD binding stabilizes the autoin-
hibitory conformation of the enzyme.
Since through its binding to the ADD domain, un-
modified histone H3 was reported to allosterically acti-
vate DNMT3A, we next investigated if TRD and histone
H3 binding to the ADD domain influence each other. For
this, we conducted pull-down experiments using GST-TRD
and DNMT3A2 in the presence of increasing concentra-
tions of recombinant histone H3. As shown in Figure 6B,
addition of histone H3 abolished the ADD–TRD interac-
tion, suggesting that H3 and TRD binding to the ADD
domain is mutually exclusive. To investigate whether his-
tone H3 can rescue the TRD-mediated inhibition, we next
conductedDNAmethylation experiments withDNMT3A2
and DNMT3A2 pre-incubated with the unmodified H3 (1–
19) peptide in the absence and presence of GST-TRD (Fig-
ure 6C). In line with the previous experiments, we observed
that the TRD-mediated inhibition is alleviated in the pres-
ence of H3 peptide (5 M). Correspondingly, the activation
of DNMT3A2–TRD complexes (which are predominantly
in the autoinhibitory conformation) is stronger than the ac-
tivation of free DNMT3A2 (which is in a mixed conforma-
tion state). Moreover, we observed that the inhibitory effect
of the TRD domain on DNMT3A activity was completely
lost at higher concentrations of the H3 peptide (25 M,
Supplementary Figure S17). This indicates that the binding
ofH3 to theADDdomain can disrupt theDNMT3A–TRD
interaction and relieve the associated enzymatic inhibition.
DISCUSSION
During the past decade compelling experimental evidence
has accumulated, indicating that DNA methylation pat-
terns are highly dynamic and result from ongoing de
novo methylation and demethylation events (3). This dy-
namic landscape plays particularly important roles in non-
dividing cells, such as terminally differentiated neurons (78–
80). In the absence of cell division andDNA replication, the
DNA methylation profiles in these cells can only be con-
trolled through a tight regulation of the targeting and activ-
ity of DNA methylating and demethylating enzymes. How-
ever, despite their importance, the details of this regulatory
network have remained mysterious so far. In this work, we
took a closer look at the DNMT3 methyltransferases, fac-
tors that play essential roles in mammalian development
and disease (1,2,81), their targeting and allosteric regulation
(6). We find that recombinant DNMT3A and DNMT3L
proteins directly and strongly interact with the chromatin
regulatorMeCP2 in vitro.We confirmed this interaction un-
der overexpression conditions inmammalian cells, as well as
at endogenous expression levels in mouse brain lysates. By
performing systematic domainmapping, we find that the in-
teraction of MeCP2 and DNMT3 proteins is mediated by
their TRD and the ADD domains, respectively. Based on
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Figure 6. Mechanism of the inhibition of DNMT3A by the MeCP2–TRD. (A) Relative in vitro activity of DNMT3A2 wild-type and its conformational
variants in the absence (dark gray) or presence (light gray) of MeCP2–TRD. The inhibition by the TRD is lost in the DNMT3A2 D531R variant, which
carries a mutation that disrupts the autoinhibitory conformation. Error bars indicate the SEM based on three independent experiments. (B) Coomassie
staining of the pull-down of His-DNMT3A2 (0.25 M) by GST-TRD in the presence of increasing concentrations of recombinant histone H3 (0, 0.26, 1.3
and 3.9M) indicating that the H3 binding toDNMT3A2 interferes with the TRD interaction. (C) DNAmethylation activity of DNMT3A2 (1M) in the
absence or presence of the H3 peptide (amino acid sequence 1–19, 5 M) or TRD (1.2 M). The two panels show the same data in different representation.
Error bars indicate the SEM based on three independent experiments. See also Supplementary Figures S16 and S17.
the fact that MeCP2 is highly expressed in neurons and it
has important functions in this cell type, the newly discov-
ered DNMT3A–MeCP2 interaction likely plays an impor-
tant role in controlling DNA methylation patterns in the
brain.
By employing in vitro methyltransferase assays using re-
combinant proteins and a variety of DNA substrates, we
observed an almost complete, concentration-dependent in-
hibitory effect caused byMeCP2 binding to DNMT3A. In-
hibition of DNMT3Awas observed on both CpG and non-
CpG substrates. Furthermore, DNMT3B activity was com-
parably reduced, proposing a conserved mode of action. To
our knowledge, MeCP2 is the first interactor of DNMT3
proteins shown to have a direct inhibitory effect on the en-
zymatic activity of these proteins. As MeCP2 is an impor-
tant reader of 5mC and 5hmC, this interaction might be re-
quired for mediating the crosstalk between 5mC/hmC sites
and DNMT3 proteins and for preventing ectopic de novo
methylation. By using engineered conformationally locked
DNMT3A variants as a novel tool to investigate DNMT3A
regulation, we show that the inhibition of DNMT3A by
MeCP2 occurs by an allosteric mechanism, in which bind-
ing of MeCP2 stabilizes the autoinhibitory conformation
of DNMT3A. Interestingly, binding of the unmodified H3
N-terminal tail peptide to the ADD domain of DNMT3A
was shown to have the opposite effect, by precluding the
autoinhibitory conformation and leading to the activation
of DNMT3A (Figure 7A) (13,14). We mechanistically ad-
dressed this crosstalk and show that binding of H3 and
TRD to DNMT3A are mutually exclusive and the MeCP2-
mediated inhibition of DNMT3A2 can be overcome by ad-
dition of the unmodified H3 tail peptide.
In summary, our data unravel one part of the intricate
regulatory network, which controls DNA methylation by
suggesting a model in which DNMT3A is under the com-
bined control of MeCP2 and the modification state of his-
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Figure 7. Model of the dual role of MeCP2 in the regulation and target-
ing of DNMT3A. (A) Binding of unmodified H3K4 to the DNMT3A–
ADD domain triggers a conformational change where the ADD moves
from the autoinhibitory (red) to the allosteric (green) interaction site and
DNA methylation can take place (purple lollipop). Model based on (13).
(B) Inhibitory role of MeCP2 on DNMT3A. Binding of MeCP2 (red) to
DNMT3A–ADD inhibits the methyltransferase by stabilizing the autoin-
hibitory conformation, thereby preventing untargeted activity. (C) Role
of MeCP2 in targeting of DNA methylation. At genomic sites with un-
modified H3K4, H3 binding to the ADD disrupts the interaction between
MeCP2 and DNMT3A leading to the activation of the enzyme and DNA
methylation (step ). MeCP2 can next bind to the methylated CpG sites
and recruit additional DNMT3A, thereby initiating a positive feedback
loop (step ).
tone H3 tails. On the one hand, the interaction withMeCP2
globally inhibits DNMT3A activity after overexpression of
MeCP2 in tissue culture (Figure 7B). This may act as a
safeguard mechanism to protect the genome from aberrant
DNA methylation. On the other hand, at specific target
sites such as repetitive sequences, where histone H3 lacks
activating marks, MeCP2 can function as a recruiter of
DNMT3 enzymes (Figure 7C). As shown by our biochem-
ical data, unmodified histone H3 can disrupt the MeCP2–
DNMT3A interaction, subsequently leading to the relief of
the allosteric inhibition. Therefore, the specific delivery of
DNMT3A to such regions by MeCP2 as visualized in the
cellular localization experiments can target DNA methy-
lation. Afterward, the elevated DNA methylation may in-
crease the methylcytosine-dependent MeCP2 recruitment
to these loci, initiating a positive feedback loop, which can
contribute to the stable maintenance of methylation at these
sites. In neurons, this process may be further supported
by the non-CpG (mainly CpA) methylation introduced by
DNMT3A, which is bound by MeCP2 as well. The oppos-
ing effect of MeCP2 on DNMT3A as potential inhibitor
and stimulator depending on the genomic context agrees
well with the dual role of MeCP2 in gene control, either as
gene repressor or activator (23,30,39,42).
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Supplementary Data are available at NAR Online.
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